Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

What Late-Breakers To Look Out For At ASCO 2019

May 16 2019

• By Alex Shimmings

Stage — Setting the Stage for ASCO 2019 • Source: Shutterstock

Related Content

Stellar Survival Data For AZ's Lynparza Hailed At ESMO

Oct 22 2018

Commercial Fallout From Merck's Failed Keytruda Gastric Cancer Trial May Be Limited

Dec 15 2017

Pfizer/Merck KGAA's Bavencio Gastric Cancer Failure Not As Bad As It Seems

Nov 29 2017

First-Line Ovarian Cancer Approval Solidifies Lead For AstraZeneca's Lynparza

Dec 19 2018

GSK Embraces PARP Promise With Tesaro Buy

Dec 03 2018

Pfizer, Astellas Accelerate Xtandi's Timeline In Early Prostate Cancer

Aug 24 2018

Lilly's Lartruvo Scores Broad FDA Approval In Orphan Sarcomas

Oct 19 2016

Erleada Keeps Pace With Xtandi After Positive TITAN Study

Jan 31 2019

Lartruvo Phase III Fail Rocks Lilly Oncology Plans

Jan 21 2019

Enfortumab Vedotin Impresses In Urothelial Cancer After Chemo, Immunotherapies

Mar 28 2019

Related Companies

AstraZeneca PLC

Merck & Co., Inc.

Pfizer Inc.

Clovis Oncology, Inc.

GSK plc

Tesaro, Inc.

Novartis AG

Astellas Pharma, Inc.

Johnson & Johnson

Seagen Inc.

Additional Topics

Clinical Trials Companies ImmunoOncology Research & Development ASCO Cancer BioPharmaceutical

More from ASCO

More from Conferences

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window